The S100 proteins such as S100A11 could promote GBM progression through ANXA2-mediated NF-κB signaling pathway (Tu et al., 2019) and S100A10 could form heterotetramers with ANXA2 to promote the activation of matrix metalloproteases (MMPs) to increase the invasive ability of tumor cells (Chen C.Y. et al., 2018). The gene discussed is S100A11; the disease is glioblastoma.